Literature DB >> 3598621

Brain metastasis in hypernephroma.

P C Gay, W J Litchy, T L Cascino.   

Abstract

Of 926 patients with hypernephroma, 36 (3.9%) had metastasis to the brain. The median age at presentation was 61 years (range, 34 to 82). Nineteen patients had a single lesion metastatic to the brain, and 16 of these lesions were supratentorial. In 28% of the patients, computed tomography showed hyperdense lesions before contrast material was injected. All patients, except 2 with incomplete records, had evidence of widespread disease involving bone, liver, or lung. The median time interval between the initial diagnosis and the discovery of brain metastasis was 65.5 weeks (range, 0 to 462), with only 2 patients initially presenting with brain metastasis. Twenty-five of the patients who received only radiation therapy had a median survival of 13 weeks (range, 4 to 146), while 7 selected patients who underwent surgical resection and postoperative radiation had a median survival of 66 weeks (range, 18 to 260). In 5 of the 7 patients, scans demonstrated recurrent tumor from 6 to 23 weeks postoperatively. One patient had a pronounced reduction in the size of the tumor after radiation therapy only. This study shows that brain metastasis is usually a late complication of hypernephroma and is associated with a poor prognosis.

Entities:  

Mesh:

Year:  1987        PMID: 3598621     DOI: 10.1007/bf00162765

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Clinical manifestations and cytology of hypernephromas.

Authors:  G P MURPHY; R H FISHBEIN
Journal:  J Urol       Date:  1961-04       Impact factor: 7.450

2.  THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES.

Authors:  O V Batson
Journal:  Ann Surg       Date:  1940-07       Impact factor: 12.969

3.  Excision of multiple intracranial metastatic hypernephroma. Report of a case with a 7-year survival.

Authors:  L A Dayes; S A Rouhe; R W Barnes
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

4.  Renal cell carcinoma.

Authors:  G W Jones
Journal:  CA Cancer J Clin       Date:  1982 Sep-Oct       Impact factor: 508.702

5.  Clinically unrecognized renal cell carcinoma. An autopsy study.

Authors:  S Hellsten; T Berge; F Linell; L Wehlin
Journal:  Prog Clin Biol Res       Date:  1982

6.  Brain metastases in patients with renal cell carcinoma: prognosis and treatment.

Authors:  D A Decker; V L Decker; A Herskovic; G D Cummings
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

7.  Metastatic processes and a potential indication of treatment for metastatic lesions of renal adenocarcinoma.

Authors:  H Saitoh; M Hida; K Nakamura; T Shimbo; T Shiramizu; T Satoh
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

8.  Renal adenocarcinoma presenting as a solitary metastasis: contribution of electron microscopy to diagnosis.

Authors:  J B Taxy
Journal:  Cancer       Date:  1981-11-01       Impact factor: 6.860

9.  Surgical treatment of single brain metastasis: factors associated with survival.

Authors:  J H Galicich; N Sundaresan; E Arbit; S Passe
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

10.  Radiation therapy for brain metastases.

Authors:  J G Cairncross; J H Kim; J B Posner
Journal:  Ann Neurol       Date:  1980-06       Impact factor: 10.422

View more
  13 in total

1.  Tc-99m Tetrofosmin SPECT for the differentiation of a cerebellar hemorrhage mimicking a brain metastasis from a renal cell carcinoma.

Authors:  G A Alexiou; J A Bokharhii; A P Kyritsis; K S Polyzoidis; A D Fotopoulos
Journal:  J Neurooncol       Date:  2006-03-31       Impact factor: 4.130

Review 2.  Current management of metastatic brain disease.

Authors:  Tulika Ranjan; Lauren E Abrey
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma.

Authors:  E K Seaman; S Ross; I S Sawczuk
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

4.  Peritumoral and intratumoral hemorrhage after stereotactic radiosurgery for renal cell carcinoma metastasis to the brain.

Authors:  Fotios Kalfas; Nello Ronchini; Tomasz Tadeusz Godowicz; Paolo Cavazzani; Paolo Severi
Journal:  J Radiosurg SBRT       Date:  2011

5.  The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.

Authors:  Jonathan Verma; Eric Jonasch; Pamela K Allen; Jeffrey S Weinberg; Nizar Tannir; Eric L Chang; Anita Mahajan
Journal:  Am J Clin Oncol       Date:  2013-12       Impact factor: 2.339

Review 6.  Solitary brain metastasis 13 years after removal of renal adenocarcinoma.

Authors:  M Ammirati; M Samii; G Skaf; A Sephernia
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

7.  Gamma knife stereotactic radiosurgery for renal cell carcinoma and melanoma brain metastases-comparison of dose response.

Authors:  Hong-Yiou Lin; Yoichi Watanabe; L Chinsoo Cho; Jianling Yuan; Matthew A Hunt; Paul W Sperduto; Aviva Abosch; Charles R Watts; Chung K Lee
Journal:  J Radiosurg SBRT       Date:  2013

Review 8.  A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases.

Authors:  Peter W Hanson; Ameer L Elaimy; Wayne T Lamoreaux; John J Demakas; Robert K Fairbanks; Alexander R Mackay; Blake Taylor; Barton S Cooke; Sudheer R Thumma; Christopher M Lee
Journal:  World J Surg Oncol       Date:  2012-08-29       Impact factor: 2.754

9.  Hepatocellular Carcinoma Metastasis to the Orbit in a Coinfected HIV+ HBV+ Patient Previously Treated with Orthotopic Liver Transplantation: A Case Report.

Authors:  S Guerriero; G Infante; E Giancipoli; S Cocchi; M G Fiore; D Piscitelli; N Cardascia
Journal:  Case Rep Ophthalmol Med       Date:  2011-12-20

Review 10.  Radiotherapy and Renal Cell Carcinoma: A Continuing Saga.

Authors:  Despoina Spyropoulou; Panagiotis Tsiganos; Foteinos-Ioannis Dimitrakopoulos; Maria Tolia; Angelos Koutras; Dimitris Velissaris; Maria Lagadinou; Nikolaos Papathanasiou; Areti Gkantaifi; Haralabos Kalofonos; Dimitrios Kardamakis
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.